Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our lab in San Diego is looking for an experienced, motivated, and versatile Drug Metabolism and Pharmacokinetics (DMPK) Director to help advance our compounds through preclinical and early clinical development with a deep expertise in in vitro ADME assays and drug metabolism pathways. The successful candidate will provide leadership and guidance in the design, analysis and reporting of in vitro and in vivo DMPK/ADMET studies to support our small molecule drug discovery and early development pipeline. The candidate will also participate in data integration best practices for AI ADME predictive model. This is a full-time position in a fast-paced biotech environment with a collegial group of high performing colleagues working towards well-defined goals. Full medical and dental benefits, flexible work hours/vacation included in this opportunity to learn all aspects of biotech start-up. Learn more about us here:https://www.genesistherapeutics.ai/ And our recent collaboration with Eli Lilly here:https://endpts.com/genentech-partnered-genesis-therapeutics-inks-newest-ai-discovery-deal-with-eli-lilly/
\n ResponsibilitiesRepresent DMPK as the technical expert on project teams, providing scientific and strategic leadership for all stages of drug discovery and early development.Support internal DMPK assay capabilities to support programs.Design, develop, execute (or manage conduct) and interpret high-throughput and mechanistic in vitro ADME assays and data to enable small molecule drug discovery efforts.Effectively manage CROs and DMPK team to design and execute in vivo studies aimed at characterizing the DMPK/ADME properties of small molecule drug candidates.Communicate DMPK data and provide interpretation of results to project teams, senior management, and other stakeholders.Oversee the preparation of nonclinical DMPK/ADME reports and the relevant sections of documents for regulatory submissions.Contribute to study designs of nonclinical pharmacology and nonclinical toxicology studies.Design, interpret and integrate pharmacokinetic (PK), pharmacokinetic/pharmacodynamic (PK/PD), and ADME data to enable estimation of human pharmacokinetics and human pharmacologically active dose.Partner with AI engineer on ADME predictive modelProvide scientific leadership and mentorship to junior staff and other functional area scientists. QualificationsA MSc or Ph.D. in Biological Science, Chemistry, Pharmacokinetics, Pharmacology or related discipline with 10+ years Industrial experience in Drug Discovery & Development.Verifiable track record of drug discovery experience, success, and leadership, with experience in advancing programs through all stages of discovery to IND candidates.Demonstrated expertise in in vitro and in vivo drug metabolism assaysThorough knowledge of FDA and ICH guidelines.Ability to work effectively in a dynamic environment with diverse team of coworkers.Solid written and oral communication skills, enthusiasm, integrity, self-motivation, strong interpersonal skills, and attention to detail are necessary.
\nGenesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules. Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets. The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has three AI platform collaborations across a range of therapeutic areas, with Gilead Sciences, Eli Lilly, and Genentech. We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.